Top Biotech Picks From Needham & Company for Second Half of 2026
Needham & Company identified five biotech stocks as top picks for the second half of 2026, all with Buy ratings. Key catalysts include clinical data readouts for Praxia Therapeutics (PRAX), Acadia Pharmaceuticals (ACAD), Biogen (BIIB), Axsome Therapeutics (AXSM), and Alkermes (ALKS). Price targets and analyst upgrades were also noted for these companies.
How this was made
The 30-second read
Why it matters
Analyst upgrades provide fresh price targets and highlight upcoming clinical milestones, offering traders actionable insight.
Market read
The picks focus on companies with imminent Phase 2/3 data, potentially moving biotech equities.
What to watch
Valuation may be stretched given the speculative nature of early‑stage trial outcomes.
Background
Needham & Company released its second‑half 2026 biotech pick list, assigning new price targets and Buy ratings.
Ticker impact
Needham maintains a Buy rating and sets a $582 price target for Praxia Therapeutics, citing upcoming Phase 3 EMERALD data readout.
upside if data readout is positive
Analyst upgrade with specific catalyst and price target.
Needham assigns a $41 price target to Acadia Pharmaceuticals ahead of Phase 2 RADIANT data readout in September/October.
potential upside on positive trial results
Analyst recommendation tied to near‑term clinical milestone.
Biogen receives a $256 price target from Needham, highlighting multiple Phase 3 readouts through 2029 and a new CRM vendor selection.
moderate upside on continued pipeline success
Analyst upgrade based on long‑term pipeline outlook.
Needham sets a $268 price target for Axsome Therapeutics, noting strong Auvelity sales and upcoming Phase 3 ENGAGE data.
upside if ENGAGE results are favorable
Analyst upgrade with specific sales and trial catalysts.
Needham assigns a $62 price target to Alkermes, citing upcoming orexin franchise data and a recent credit agreement amendment.
potential upside on positive trial readout
Analyst upgrade linked to near‑term clinical and financial developments.
Market effects
Highlights bullish outlook for biotech sector based on multiple pipeline catalysts.
U.S. biotech equities may see increased buying pressure.
Potential spillover to global biotech investors tracking U.S. trial data.
Counterpoint
If trial readouts miss expectations, the high price targets could lead to sharp corrections.
Key entities
- Research FirmNeedham & Company
Equity research firm issuing the picks.
